Published in Med Arch on August 04, 2015
Cystic fibrosis. N Engl J Med (2005) 8.09
Cystic fibrosis: a worldwide analysis of CFTR mutations--correlation with incidence data and application to screening. Hum Mutat (2002) 5.43
Cystic fibrosis. Lancet (2009) 5.40
Mucoid Pseudomonas aeruginosa is a marker of poor survival in cystic fibrosis. Pediatr Pulmonol (1992) 3.00
Cystic fibrosis mortality and survival in the UK: 1947-2003. Eur Respir J (2006) 2.54
Longevity of patients with cystic fibrosis in 2000 to 2010 and beyond: survival analysis of the Cystic Fibrosis Foundation patient registry. Ann Intern Med (2014) 2.15
The prevalence of cystic fibrosis in the European Union. J Cyst Fibros (2008) 1.87
A survey of newborn screening for cystic fibrosis in Europe. J Cyst Fibros (2006) 1.70
Chronic ataluren (PTC124) treatment of nonsense mutation cystic fibrosis. Eur Respir J (2011) 1.63
Risk factors for death of patients with cystic fibrosis awaiting lung transplantation. Am J Respir Crit Care Med (2005) 1.30
VX-809 corrects folding defects in cystic fibrosis transmembrane conductance regulator protein through action on membrane-spanning domain 1. Mol Biol Cell (2013) 1.29
Is there still a gender gap in cystic fibrosis? Chest (2005) 1.16
Cystic fibrosis: pathogenesis and future treatment strategies. Respir Care (2009) 1.11
The relevance of sweat testing for the diagnosis of cystic fibrosis in the genomic era. Clin Biochem Rev (2005) 0.97
Ivacaftor: the first therapy acting on the primary cause of cystic fibrosis. Drugs Today (Barc) (2013) 0.91
Pathogenesis of early lung disease in cystic fibrosis: a window of opportunity to eradicate bacteria. Ann Intern Med (2005) 0.86
Diagnosis of cystic fibrosis. Clin Rev Allergy Immunol (2008) 0.85
Test for the concentration of electrolytes in cystic fibrosis of the pancreas utilizing pilocarpine by iontophoresis, by Lewis E. Gibson and Robert E. Cooke, Pediatrics; 1959;24:545-549. Pediatrics (1998) 0.78